SCHEMBL1978577

SCHEMBL1978577

C#CCOCc1cccc([N+](=O)[O-])c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PYCR1 P32322 1/20 0.55
TSHR P16473 3/20 0.53
MAOB P27338 2/20 0.48
MAOA P21397 1/20 0.48
ALDH1A1 P00352 4/20 0.47
KMT2A Q03164 3/20 0.47
MEN1 O00255 2/20 0.47
MAPT P10636 2/20 0.47
MAPK1 P28482 1/20 0.47
LMNA P02545 1/20 0.47
TDP1 Q9NUW8 1/20 0.45
ALOX15 P16050 1/20 0.45
RAB9A P51151 1/20 0.44
RXFP1 Q9HBX9 1/20 0.44
F2 P00734 1/20 0.44
ALOX5 P09917 1/20 0.44
CYP1A2 P05177 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1767329 0.85 TSHR (0.65) TSHRMAOBMAOAALDH1A1KMT2A
SCHEMBL7861196 0.81 TSHR (0.59) TSHRMAOBMAOAALDH1A1KMT2A
SCHEMBL6141028 0.81 IDO1 (0.56) PYCR1TSHRMAOBALDH1A1MAPT
SCHEMBL3147589 0.80 TSHR (0.57) TSHRMAOBMAOAALDH1A1KMT2A
SCHEMBL11503161 0.80 TSHR (0.67) TSHRMAOBMAOAALDH1A1KMT2A
SCHEMBL28381738 0.80 TSHR (0.57) TSHRMAOBMAOAALDH1A1KMT2A
SCHEMBL18714233 0.80 TSHR (0.57) TSHRMAOBMAOAALDH1A1KMT2A
SCHEMBL3721964 0.80 TSHR (0.57) PYCR1TSHRMAOBMAOAALDH1A1
SCHEMBL7206952 0.79 PYCR1 (0.61) PYCR1TSHRALDH1A1KMT2AMEN1
SCHEMBL791926 0.77 TSHR (0.62) PYCR1TSHRMAOBMAOAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2334301-B1 MACROCYCLICS PYRIMIDINES AS AURORA KINASE INHIBITORS MERCK SERONO SA (CH) 2018-02-14 EP disclosed
US-8815872-B2 Macrocyclics pyrimidines as aurora kinase inhibitors MERCK PATENT GMBH (DE) 2014-08-26 US disclosed
US-8815872-B2 Macrocyclics pyrimidines as aurora kinase inhibitors MERCK PATENT GMBH (DE) 2014-08-26 US disclosed
US-8815872-B2 Macrocyclics pyrimidines as aurora kinase inhibitors MERCK PATENT GMBH (DE) 2014-08-26 US disclosed
US-20110294801-A1 MACROCYCLICS PYRIMIDINES AS AURORA KINASE INHIBITORS MERCK PATENT GMBH (DE) 2011-12-01 US disclosed
US-20110294801-A1 MACROCYCLICS PYRIMIDINES AS AURORA KINASE INHIBITORS MERCK PATENT GMBH (DE) 2011-12-01 US disclosed
US-20110294801-A1 MACROCYCLICS PYRIMIDINES AS AURORA KINASE INHIBITORS MERCK PATENT GMBH (DE) 2011-12-01 US disclosed
EP-2334301-A1 MACROCYCLICS PYRIMIDINES AS AURORA KINASE INHIBITORS Merck Serono SA (CH) 2011-06-22 EP disclosed
WO-2010028116-A1 MACROCYCLICS PYRIMIDINES AS AURORA KINASE INHIBITORS MERCK SERONO S.A. (CH) 2010-03-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110294801-A1 MACROCYCLICS PYRIMIDINES AS AURORA KINASE INHIBITORS AURKC, AURKA, AURKB PYCR1 1974/4885TSHR 3505/4885MAOB 2486/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.